4SC AG

4SC AG (FRA:VSC) filed a marketing authorization application for Resminostat with the EMA, received orphan drug designation in Switzerland, and showed positive RESMAIN study results. Operating costs were reduced by 18%, but the company reported a loss of EUR4 million in H1 2024. Decided not to pursue Resminostat registration in the US due to FDA response, and faces financial challenges with high monthly cash usage.

4SC AG plans to issue 792,080 new shares, raising approx. EUR 4 million, to fund drug development. Main shareholder Santo Holding (Deutschland) GmbH will subscribe at EUR 5.05 per share. Registration expected on 17 September 2024, with trading starting 24 September.